Agios Pharmaceuticals Inc AGIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AGIO is a good fit for your portfolio.
News
-
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
-
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
-
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
-
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
-
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
-
Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder
Trading Information
- Previous Close Price
- $31.67
- Day Range
- $31.22–32.25
- 52-Week Range
- $19.80–35.50
- Bid/Ask
- $12.64 / $34.57
- Market Cap
- $1.78 Bil
- Volume/Avg
- 721,957 / 765,718
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 65.71
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 386
- Website
- https://www.agios.com
Comparables
Valuation
|
Metric
|
AGIO
|
KDNY
|
RCKT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.18 | 7.59 | 4.34 |
Price/Sales | 65.71 | 482.40 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AGIO
|
KDNY
|
RCKT
|
|---|---|---|---|
Quick Ratio | 11.47 | 5.72 | 7.69 |
Current Ratio | 12.27 | 5.82 | 7.80 |
Interest Coverage | — | — | −138.48 |
Quick Ratio
AGIO
KDNY
RCKT
Profitability
|
Metric
|
AGIO
|
KDNY
|
RCKT
|
|---|---|---|---|
Return on Assets (Normalized) | −28.30% | −37.41% | −38.11% |
Return on Equity (Normalized) | −31.96% | −47.73% | −43.04% |
Return on Invested Capital (Normalized) | −32.74% | −43.85% | −43.72% |
Return on Assets
AGIO
KDNY
RCKT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gnfpvndfz | Tfbx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xkbgrpzr | Qwfyy | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cwmpnrr | Lwfqbs | $97.8 Bil | |
MRNA
| Moderna Inc | Nwfcctdf | Qhfv | $38.8 Bil | |
ARGX
| argenx SE ADR | Tzhhxykm | Nbx | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Qlscmhtt | Gbqql | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xhjkknxl | Kqvwrn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sdtxkrs | Qypkk | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cwwnjbhsy | Dkmznm | $12.5 Bil | |
INCY
| Incyte Corp | Ppghzlq | Dpfkj | $11.5 Bil |